Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
14 participants
INTERVENTIONAL
2015-09-30
2016-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Barley Based Food Products on Metabolism and Gut Microflora
NCT02427555
Effects of Whole Grain Rye on Metabolic Risk Markers and Mood
NCT03275948
The Influence of Daily Intake of Whole Grain Barley or Oats on Biomarkers of Cardiovascular Disease
NCT01293604
β-Glucans and the Metabolic Syndrome - a Human Intervention Study Under BEST
NCT01317264
Determining the Potential of Wholegrain Wheat and Rye to Improve Gut HealTh
NCT02358122
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The intervention was designed as a randomized, cross over trial of 3-weeks duration. A total of 14 participants was included in the study. In one period subjects received WBB bread; in the second period, subjects received WWB bread. This bread is based on the recipe of Egyptian Baladi bread but formed in Danish buns form. Participants incorporated this bread into their normal habitual diet with regard to the study restrictions about other cereal food products. At the beginning and end of each intervention period blood was drawn and urine collected and stored for later analysis.
The primary outcomes of this study are evaluation of LDL-c, insulin and glucose levels evaluated by analysis of fasting blood samples. Furthermore, selected measures to evaluate SCFA level in blood is to be evaluated. Secondary outcomes include mineral status.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Barley bread
Two loaves, 2 x 120 g loaf/day for 3 weeks.
Barley bread
120g barley bread per day for 3 weeks.
Wheat bread
Two loaves, 2 x 120 g loaf/day for 3 weeks.
Wheat bread
120g wheat bread per day for 3 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Barley bread
120g barley bread per day for 3 weeks.
Wheat bread
120g wheat bread per day for 3 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age: 20 - 53 years
* Body mass index (BMI): 23 - 30 kg/m2
* Weight stable (\<3 kg weight change during the last 6 months)
* Apparently healthy
* Informed consent signed
* Freezer capacity for 1 week bread provision
* Can attend all visits required for the study
Exclusion Criteria
* Smoking on a daily basis
* Lactating (or lactating within 6 weeks prior to study start), pregnant (or pregnant within 3 months prior to study start) or wish to become pregnant during the study
* Diagnosed with any form of diabetes or cardiovascular disease
* Reported chronic gastrointestinal disorders
* Taking dietary supplements during or one month prior to the study
* Lack of cooperation and adherence to the protocol
* Use of prescription medication will be evaluated on an individual basis
* Blood donation within 3 months prior to study start or during the study
* Participation in other clinical trials
20 Years
53 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Arne Astrup
Professor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-15010303
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.